Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
October 27, 2021 02:15 ET | Curium
St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3...
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
August 24, 2021 02:15 ET | Curium
ST. LOUIS, MO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Curium announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Cu-64...
RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
May 05, 2021 10:50 ET | Curium
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN)...
RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
May 05, 2021 02:30 ET | Curium
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN)...
Curium Announces Filing of a Generic Version of DaTscanᵀᴹ (Ioflupane I 123 Injection) in the U.S.
May 04, 2021 02:30 ET | Curium
St. Louis, MO, May 04, 2021 (GLOBE NEWSWIRE) -- Curium announced today that it submitted an abbreviated new drug application for a generic version of DaTscan (Ioflupane I 123 Injection) with the...
Curium to Expand Noblesville Facility’s Workforce
April 28, 2021 02:30 ET | Curium
St. Louis, MO, April 28, 2021 (GLOBE NEWSWIRE) -- Curium, the world’s largest nuclear medicine company, has announced plans to invest in new jobs at its Noblesville location – furthering its...
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
March 01, 2021 19:15 ET | Curium
Berlin, Germany and Paris, France, March 01, 2021 (GLOBE NEWSWIRE) -- Eckert & Ziegler Radiopharma GmbH and Curium PET France have decided to reinforce their existing long term partnership by...
RadioMedix & Curium Announce Permanent HCPCS Code for DetectnetTM (copper Cu 64 dotatate injection)
January 26, 2021 02:30 ET | Curium
St. Louis, MO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has granted Detectnet a...
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
September 08, 2020 13:52 ET | Curium
Houston, TX and St. Louis, MO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that DetectnetTM (copper Cu 64 dotatate injection) was approved by...
Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe.
June 09, 2020 07:00 ET | Curium
St. Louis, MO, June 09, 2020 (GLOBE NEWSWIRE) -- Curium announced today that it has filed the first stand-alone Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) and has also...